Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8065494rdf:typepubmed:Citationlld:pubmed
pubmed-article:8065494lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C0031381lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C1705938lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C1527178lld:lifeskim
pubmed-article:8065494lifeskim:mentionsumls-concept:C0813872lld:lifeskim
pubmed-article:8065494pubmed:issue4lld:pubmed
pubmed-article:8065494pubmed:dateCreated1994-9-19lld:pubmed
pubmed-article:8065494pubmed:abstractTextThe electrophilic affinity ligand, (+)-3-isothiocyanato-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycl ohepten-5,10 - imine hydrochloride [(+)-MK801-NCS] was characterized for its ability to acrylate phencyclidine (PCP) and sigma binding sites in vivo. Initial studies, conducted with mouse brain membranes, characterized the binding sites labeled by [3H]1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP). The Kd values of [3H]TCP for PCP site 1 (MK801-sensitive) and PCP site 2 (MK801-insensitive) were 12 nM and 68 nM, with Bmax values of 1442 and 734 fmol/mg protein, respectively. Mice were sacrificed 18-24 hours following intracerebroventricular administration of the acylator. The administration of (+)-MK801-NCS increased [3H]TCP binding to site 2, but not to site 1. Although (+)-MK801-NCS decreased [3H](+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d; ccyclohepten-5,10-imine maleate ([3H](+)-MK801) binding to site 1, it had no effect on [3H]TCP binding to site 1. Viewed collectively with other published data, these data support the hypothesis that PCP sites 1 and 2 are distinct binding sites, and that [3H]TCP and [3H](+)-MK801 label different domains of the PCP binding site associated with the NMDA receptor.lld:pubmed
pubmed-article:8065494pubmed:languageenglld:pubmed
pubmed-article:8065494pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:citationSubsetIMlld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8065494pubmed:statusMEDLINElld:pubmed
pubmed-article:8065494pubmed:monthAprlld:pubmed
pubmed-article:8065494pubmed:issn0364-3190lld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:JacobsonA EAElld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:RiceK CKClld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:RothmanR BRBlld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:JiangQQlld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:MonnJ AJAlld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:PorrecaFFlld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:AkunneH CHClld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:ThurkaufAAlld:pubmed
pubmed-article:8065494pubmed:authorpubmed-author:LindersJ TJTlld:pubmed
pubmed-article:8065494pubmed:issnTypePrintlld:pubmed
pubmed-article:8065494pubmed:volume19lld:pubmed
pubmed-article:8065494pubmed:ownerNLMlld:pubmed
pubmed-article:8065494pubmed:authorsCompleteYlld:pubmed
pubmed-article:8065494pubmed:pagination385-9lld:pubmed
pubmed-article:8065494pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:meshHeadingpubmed-meshheading:8065494-...lld:pubmed
pubmed-article:8065494pubmed:year1994lld:pubmed
pubmed-article:8065494pubmed:articleTitleAn electrophilic affinity ligand based on (+)-MK801 distinguishes PCP site 1 from PCP site 2.lld:pubmed
pubmed-article:8065494pubmed:affiliationClinical Psychopharmacology Section, NIDA/NIH Addiction Research Center, Baltimore, MD 21224.lld:pubmed
pubmed-article:8065494pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8065494pubmed:publicationTypeComparative Studylld:pubmed